Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone hydrochloride liposome + rituximab + bendamustine in relapsed/refractory DLBCL
ChiCTR2300073448Phase 4Not yet recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mitoxantrone, rituximab and bendamustine in diffuse large B-cell lymphoma (DLBCL), sponsored by Chongqing University Cancer Hospital. Primary endpoint: Maximum tolerated dose. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
mitoxantronerituximabbendamustine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2300073448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073448.